Best-selling drugs in 2025: Keytruda tops another list

GlobalData's Pharmaceutical Intelligence Center released a list predicting what the best-selling drugs will be in 2025, according to EndPoints News.

Topping the list is Keytruda, Merck's cancer immunotherapy, which GlobalData anticipates will reach $22.2 billion in sales by 2025. 

Here is the full list:

1. Keytruda ($22.2 billion)

2. Eliquis ($18.7 billion)

3. Revlimid ($12.4 billion)

4. Opdivo ($12 billion)

5. Imbruvica ($11.9 billion)

6. Humira ($10.3 billion)

7. Biktarvy ($10 billion)

8. Ibrance ($9 billion)

9. Stelara ($7.5 billion)

10. Trulicity ($7.2 billion)

More articles on pharmacy:
Telemedicine startup to open first brick-and-mortar pharmacy
Top 10 pharmacy stories in September
Novant Health to open health clinics inside Walgreens

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers